Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 16INDUSTRY 8OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 8Stomach Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Pathologic Complete Response 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1HER2 Positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1EGFR Positive Non-small Cell Lung Cancer 1Breast Diseases 1Advanced Non-small-cell Lung Cancer 1Advanced Gastric Cancer 1

Interventions

Cisplatin 3sintilimab 2toripalimab 1camrelizumab 1anlotinib 1TP protocol 1Radiotherapy 1Radiation 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Immune Checkpoint Inhibitors 1Fluorouracil 1Docetaxel 1Chemoradiotherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Esophageal Squamous Cell Carcinoma × Docetaxel × Clear all
NCT03914443 2025-05-31

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

National Cancer Center, Japan

Phase 1 Completed
37 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡